NEW YORK (TheStreet) -- Shares of Metlife (MET) are down 0.24% to $53.90 after the Financial Oversight Stability Council voted yesterday 9 to 1 to label the largest U.S. insurer as "systemically important," subjecting the company to closer review by the Federal Reserve.
MetLife said it is "disappointed" by the ruling and believes it has presented "substantial and compelling evidence" that any future financial problem wouldn't jolt the U.S. economy during a time of stress, the Wall Street Journal reported.
MetLife's lawyers have been working for weeks on a potential lawsuit that would challenge the government's designation while MetLife executives and directors debated the pros and cons of going to court, sources told the Journal.
Exclusive Report: Jim Cramer's Best Stocks for 2015
Additionally, it was reported that the insurer could disrupt markets if it was forced to sell off illiquid assets should it land into trouble, according to a report by U.S. regulators today, according to Reuters.
Separately, TheStreet Ratings team rates METLIFE INC as a Buy with a ratings score of A. TheStreet Ratings Team has this to say about their recommendation:
"We rate METLIFE INC (MET) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, attractive valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins."